Gland Pharma Limited

rs 25

LIMITED August 07, 2023 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

57%

ns (INR Mn) Gross Profit (1) / Gross Profit Margin (2) (INR Mn / %) 12,087 12,087 8,569 7,850 57% 7,558 63% 4,828 56% 80% 7,558 63% 4,202 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23

63%

Gross Profit (1) / Gross Profit Margin (2) (INR Mn / %) 12,087 12,087 8,569 7,850 57% 7,558 63% 4,828 56% 80% 7,558 63% 4,202 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4

56%

t (1) / Gross Profit Margin (2) (INR Mn / %) 12,087 12,087 8,569 7,850 57% 7,558 63% 4,828 56% 80% 7,558 63% 4,202 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY2

80%

/ Gross Profit Margin (2) (INR Mn / %) 12,087 12,087 8,569 7,850 57% 7,558 63% 4,828 56% 80% 7,558 63% 4,202 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 EB

54%

2) (INR Mn / %) 12,087 12,087 8,569 7,850 57% 7,558 63% 4,828 56% 80% 7,558 63% 4,202 54% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 EBITDA (3) / EBITDA Margin

10%

Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) 10% 2,699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,9

31%

FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) 10% 2,699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,941 16% 29%

25%

23 Q1 FY24 Q4 FY23 Q1 FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) 10% 2,699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,941 16% 29% 28% 787

21%

4) (INR Mn / %) 10% 2,699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,941 16% 29% 28% 787 10% 1,941 16% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY2

27%

%) 10% 2,699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,941 16% 29% 28% 787 10% 1,941 16% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24

16%

699 31% 2,982 25% PAT / PAT Margin (5) (INR Mn / %) 2,982 25% 1,684 21% 2,292 27% 1,941 16% 29% 28% 787 10% 1,941 16% Q1 FY23 Q1 FY24 Q4 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q4 FY23 Q1

Corporate Office

2

Regd. Office

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND] GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q1’FY24 07th August 2023 Ge«ncit»Mi Injection ; GemtiUfr t«|echoa Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to dif

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India BSE 543245 ®NSE GLAND Bloomberg GLAND:IN 14